{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:26:08Z","timestamp":1774527968404,"version":"3.50.1"},"reference-count":108,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nanomaterials"],"abstract":"<jats:p>Due the implementation of nanotechnologies in the pharmaceutical industry over the last few decades, new type of cutting-edge formulations\u2014nanopharmaceutics\u2014have been proposed. These comprise pharmaceutical products at the nanoscale, developed from different types of materials with the purpose to, e.g., overcome solubility problems of poorly water-soluble drugs, the pharmacokinetic and pharmacodynamic profiles of known drugs but also of new biomolecules, to modify the release profile of loaded compounds, or to decrease the risk of toxicity by providing site-specific delivery reducing the systemic distribution and thus adverse side effects. To succeed with the development of a nanopharmaceutical formulation, it is first necessary to analyze the type of drug which is to be encapsulated, select the type matrix to load it (e.g., polymers, lipids, polysaccharides, proteins, metals), followed by the production procedure. Together these elements have to be compatible with the administration route. To be launched onto the market, the selected production method has to be scaled-up, and quality assurance implemented for the product to reach clinical trials, during which in vivo performance is evaluated. Regulatory issues concerning nanopharmaceutics still require expertise for harmonizing legislation and a clear understanding of clinically compliant production methods. The first part of this study addressing \u201cNanopharmaceutics: Part I\u2014Clinical trials legislation and Good Manufacturing Practices (GMP) of nanotherapeutics in the EU\u201d has been published in Pharmaceutics. This second part complements the study with the discussion about the production scales and clinically compliant production methods of nanopharmaceutics.<\/jats:p>","DOI":"10.3390\/nano10030455","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T10:46:08Z","timestamp":1583318768000},"page":"455","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Nanopharmaceutics: Part II\u2014Production Scales and Clinically Compliant Production Methods"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9737-6017","authenticated-orcid":false,"given":"Eliana B.","family":"Souto","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, P\u00f3lo das Ci\u00eancias da Sa\u00fade, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal"},{"name":"CEB-Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-9722","authenticated-orcid":false,"given":"Gabriela F.","family":"Silva","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, P\u00f3lo das Ci\u00eancias da Sa\u00fade, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8502-8701","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Dias-Ferreira","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, P\u00f3lo das Ci\u00eancias da Sa\u00fade, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2603-1377","authenticated-orcid":false,"given":"Aleksandra","family":"Zielinska","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, P\u00f3lo das Ci\u00eancias da Sa\u00fade, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5699-0387","authenticated-orcid":false,"given":"F\u00e1tima","family":"Ventura","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Human Biology, Faculty of Pharmacy of University of Lisbon, 1649-003 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7747-9107","authenticated-orcid":false,"given":"Alessandra","family":"Durazzo","sequence":"additional","affiliation":[{"name":"CREA-Research Centre for Food and Nutrition, Via Ardeatina 546, 00178 Rome, Italy"}]},{"given":"Massimo","family":"Lucarini","sequence":"additional","affiliation":[{"name":"CREA-Research Centre for Food and Nutrition, Via Ardeatina 546, 00178 Rome, Italy"}]},{"given":"Ettore","family":"Novellino","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Napoli, Italy"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5505-3327","authenticated-orcid":false,"given":"Antonello","family":"Santini","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Napoli, Italy"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"key":"ref_1","first-page":"191","article-title":"Nanomedicines in the European translational process","volume":"7","author":"Amenta","year":"2015","journal-title":"Eur. J. Nanomed."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4161\/mabs.3.3.15474","article-title":"Regulatory pathways in the European Union","volume":"3","author":"Kohler","year":"2011","journal-title":"mAbs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00228-015-1904-1","article-title":"An analysis of marketing authorisation applications via the mutual recognition and decentralised procedures in Europe","volume":"71","author":"Ebbers","year":"2015","journal-title":"Eur. J. Clin. Pharm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1158\/1078-0432.CCR-14-0521","article-title":"Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee","volume":"20","author":"Paller","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/jnci\/djr218","article-title":"Randomized Phase II Trials: A Long-term Investment with Promising Returns","volume":"103","author":"Sharma","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10985-007-9049-x","article-title":"A review of phase 2\u20133 clinical trial designs","volume":"14","author":"Thall","year":"2008","journal-title":"Lifetime Data Anal."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.techfore.2012.05.002","article-title":"The pharmaceutical technology landscape: A new form of technology roadmapping","volume":"80","author":"Tierney","year":"2013","journal-title":"Technol. Forecast. Soc. Chang."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3810\/pgm.2011.09.2475","article-title":"Key Concepts of Clinical Trials: A Narrative Review","volume":"123","author":"Umscheid","year":"2011","journal-title":"Postgrad. Med."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Souto, E.B., Freitas, G., Dias-Ferreira, J., Zielinska, A., Ventura, F., Lucarini, M., Novellino, E., and Santini, A. (2020). Nanopharmaceutics: Part I\u2014Clinical trials legislation and good manufacturing practices (GMP) of nanotherapeutics in the EU. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12020146"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejps.2005.03.013","article-title":"Comparative scale-up of three methods for producing ibuprofen-loaded nanoparticles","volume":"25","author":"Puel","year":"2005","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/acs.bioconjchem.5b00607","article-title":"Transforming Nanomedicines From Lab Scale Production to Novel Clinical Modality","volume":"27","author":"Peer","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/nnano.2009.242","article-title":"Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective","volume":"4","author":"Auffan","year":"2009","journal-title":"Nat. Nanotechnol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plipres.2017.07.001","article-title":"Beyond liposomes: Recent advances on lipid based nanostructures for poorly soluble\/poorly permeable drug delivery","volume":"68","author":"Teixeira","year":"2017","journal-title":"Prog. Lipid Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ijpharm.2014.08.001","article-title":"Nanoemulsions (NEs), liposomes (LPs) and solid lipid nanoparticles (SLNs) for retinyl palmitate: Effect on skin permeation","volume":"473","author":"Clares","year":"2014","journal-title":"Int. J. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.colsurfb.2018.07.049","article-title":"Mixed cationic liposomes for brain delivery of drugs by the intranasal route: The acetylcholinesterase reactivator 2-PAM as encapsulated drug model","volume":"171","author":"Pashirova","year":"2018","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"118953","DOI":"10.1016\/j.ijpharm.2019.118953","article-title":"Synthesis, structure-activity relationship and biological evaluation of tetracationic gemini Dabco-surfactants for transdermal liposomal formulations","volume":"575","author":"Pashirova","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.colsurfb.2015.03.062","article-title":"Nanoemulsions for dermal controlled release of oleanolic and ursolic acids: In vitro, ex vivo and in vivo characterization","volume":"130","author":"Alvarado","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3109\/10837450.2013.823989","article-title":"Nanoemulsions for delivery of flavonoids: Formulation and in vitro release of rutin as model drug","volume":"19","author":"Macedo","year":"2014","journal-title":"Pharm. Dev. Technol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zielinska, A., Ferreira, N.R., Durazzo, A., Lucarini, M., Cicero, N., Mamouni, S.E., Silva, A.M., Nowak, I., Santini, A., and Souto, E.B. (2019). Development and Optimization of Alpha-Pinene-Loaded Solid Lipid Nanoparticles (SLN) Using Experimental Factorial Design and Dispersion Analysis. Molecules, 24.","DOI":"10.3390\/molecules24152683"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"110705","DOI":"10.1016\/j.colsurfb.2019.110705","article-title":"Dual-drugs delivery in solid lipid nanoparticles for the treatment of Candida albicans mycosis","volume":"186","author":"Carbone","year":"2019","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ijpharm.2018.10.065","article-title":"Anti-inflammatory and anti-cancer activity of citral: Optimization of citral-loaded solid lipid nanoparticles (SLN) using experimental factorial design and LUMiSizer(R)","volume":"553","author":"Zielinska","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejpb.2016.10.009","article-title":"Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye\u2014Part I\u2014Barriers and determining factors in ocular delivery","volume":"110","author":"Espina","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejpb.2016.10.013","article-title":"Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye\u2014Part II\u2014Ocular drug-loaded lipid nanoparticles","volume":"110","author":"Espina","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Vieira, R., Severino, P., Nalone, L.A., Souto, S.B., Silva, A.M., Lucarini, M., Durazzo, A., Santini, A., and Souto, E.B. (2020). Sucupira Oil-Loaded Nanostructured Lipid Carriers (NLC): Lipid Screening, Factorial Design, Release Profile, and Cytotoxicity. Molecules, 25.","DOI":"10.3390\/molecules25030685"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejpb.2016.08.001","article-title":"Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation","volume":"108","author":"Doktorovova","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2014.02.005","article-title":"Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers\u2014A systematic review of in vitro data","volume":"87","author":"Doktorovova","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/jat.2961","article-title":"Comet assay reveals no genotoxicity risk of cationic solid lipid nanoparticles","volume":"34","author":"Doktorovova","year":"2014","journal-title":"J. Appl. Toxicol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1080\/10837450.2017.1384491","article-title":"Hansen solubility parameters (HSP) for prescreening formulation of solid lipid nanoparticles (SLN): In vitro testing of curcumin-loaded SLN in MCF-7 and BT-474 cell lines","volume":"23","author":"Doktorovova","year":"2018","journal-title":"Pharm. Dev. Technol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1166\/jbn.2009.443","article-title":"Improving oral absorption of Salmon calcitonin by trimyristin lipid nanoparticles","volume":"5","author":"Martins","year":"2009","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.addr.2007.04.007","article-title":"Solid lipid nanoparticles as a drug delivery system for peptides and proteins","volume":"59","author":"Almeida","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/10837450.2018.1549075","article-title":"Optimization of nimesulide-loaded solid lipid nanoparticles (SLN) by factorial design, release profile and cytotoxicity in human Colon adenocarcinoma cell line","volume":"24","author":"Campos","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.nano.2011.10.015","article-title":"Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): In vitro and ex vivo studies","volume":"8","author":"Araujo","year":"2012","journal-title":"Nanomedicine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-3-642-00477-3_4","article-title":"Lipid nanoparticles: Effect on bioavailability and pharmacokinetic changes","volume":"197","author":"Souto","year":"2010","journal-title":"Handb. Exp. Pharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijpharm.2004.02.032","article-title":"Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery","volume":"278","author":"Souto","year":"2004","journal-title":"Int. J. Pharm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejps.2018.11.022","article-title":"Surface-tailored anti-HER2\/neu-solid lipid nanoparticles for site-specific targeting MCF-7 and BT-474 breast cancer cells","volume":"128","author":"Souto","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Souto, E.B., Souto, S.B., Zielinska, A., Durazzo, A., Lucarini, M., Santini, A., Horba\u0144czuk, O.K., Atanasov, A.G., Marques, C., and Andrade, L.N. (2020). Perillaldehyde 1,2-epoxide loaded SLN-tailored mAb: Production, physicochemical characterization and in vitro cytotoxicity profile in MCF-7 cell lines. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12020161"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ataide, J.A., Gerios, E.F., Cefali, L.C., Fernandes, A.R., Teixeira, M.D.C., Ferreira, N.R., Tambourgi, E.B., Jozala, A.F., Chaud, M.V., and Oliveira-Nascimento, L. (2019). Effect of Polysaccharide Sources on the Physicochemical Properties of Bromelain-Chitosan Nanoparticles. Polymers, 11.","DOI":"10.3390\/polym11101681"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.colsurfb.2011.11.040","article-title":"Cross-linked chitosan microspheres for oral delivery of insulin: Taguchi design and in vivo testing","volume":"92","author":"Jose","year":"2012","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.colsurfb.2010.11.033","article-title":"Colon specific chitosan microspheres for chronotherapy of chronic stable angina","volume":"83","author":"Jose","year":"2011","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1701808","DOI":"10.1002\/smll.201701808","article-title":"Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma","volume":"14","author":"Egea","year":"2018","journal-title":"Small"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ijpharm.2016.07.055","article-title":"In vitro, ex vivo and in vivo characterization of PLGA nanoparticles loading pranoprofen for ocular administration","volume":"511","author":"Canadas","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejpb.2015.01.026","article-title":"Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration","volume":"95","author":"Abrego","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejps.2014.06.024","article-title":"Surface modified PLGA nanoparticles for brain targeting of Bacoside-A","volume":"63","author":"Jose","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.2174\/1381612821666150531163617","article-title":"Hydrophilic Polymers for Modified-Release Nanoparticles: A Review of Mathematical Modelling for Pharmacokinetic Analysis","volume":"21","author":"Andreani","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12951-018-0356-z","article-title":"Memantine loaded PLGA PEGylated nanoparticles for Alzheimer\u2019s disease: In vitro and in vivo characterization","volume":"16","author":"Ettcheto","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.colsurfb.2016.04.054","article-title":"PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen-in vitro, ex vivo and in vivo characterization","volume":"145","author":"Egea","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Jose, S., Cinu, T.A., Sebastian, R., Shoja, M.H., Aleykutty, N.A., Durazzo, A., Lucarini, M., Santini, A., and Souto, E.B. (2019). Transferrin-Conjugated Docetaxel-PLGA Nanoparticles for Tumor Targeting: Influence on MCF-7 Cell Cycle. Polymers, 11.","DOI":"10.3390\/polym11111905"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Silva, A.M., Alvarado, H.L., Abrego, G., Martins-Gomes, C., Garduno-Ramirez, M.L., Garcia, M.L., Calpena, A.C., and Souto, E.B. (2019). In Vitro Cytotoxicity of Oleanolic\/Ursolic Acids-Loaded in PLGA Nanoparticles in Different Cell Lines. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11080362"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2174\/1381612825666190425163424","article-title":"Alginate Nanoparticles for Drug Delivery and Targeting","volume":"25","author":"Severino","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jconrel.2019.03.010","article-title":"Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)\/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe\/PS1dE9 Alzheimer\u2019s disease mice model","volume":"301","author":"Cano","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Souto, E.B., Ribeiro, A.F., Ferreira, M.I., Teixeira, M.C., Shimojo, A.A.M., Soriano, J.L., Naveros, B.C., Durazzo, A., Lucarini, M., and Souto, S.B. (2020). New Nanotechnologies for the Treatment and Repair of Skin Burns Infections. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21020393"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.msec.2015.11.034","article-title":"Design and characterization of chitosan\/zeolite composite films\u2014Effect of zeolite type and zeolite dose on the film properties","volume":"60","author":"Barbosa","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery\u2014A review of the state of the art","volume":"50","author":"Gohla","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"815","DOI":"10.3109\/03639045.2010.545414","article-title":"Physicochemical properties of lipid nanoparticles: Effect of lipid and surfactant composition","volume":"37","author":"Martins","year":"2011","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1080\/10837450.2019.1647235","article-title":"Key production parameters for the development of solid lipid nanoparticles by high shear homogenization","volume":"24","author":"Souto","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.msec.2012.04.017","article-title":"Optimizing SLN and NLC by 2(2) full factorial design: Effect of homogenization technique","volume":"32","author":"Severino","year":"2012","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/02652040500435295","article-title":"Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization","volume":"23","author":"Souto","year":"2006","journal-title":"J. Microencapsul."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/17425247.2020.1727883","article-title":"SLN and NLC for topical, dermal and transdermal drug delivery","volume":"17","author":"Souto","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1166\/jbn.2007.049","article-title":"Lipid Nanoparticles (SLN\u00ae, NLC\u00ae) for Cutaneous Drug Delivery:Structure, Protection and Skin Effects","volume":"3","author":"Souto","year":"2007","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jconrel.2005.07.023","article-title":"Preparation of solid lipid nanoparticles using a membrane contactor","volume":"108","author":"Charcosset","year":"2005","journal-title":"J. Control. Release"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Chirio, D., Peira, E., Dianzani, C., Muntoni, E., Gigliotti, C.L., Ferrara, B., Sapino, S., Chindamo, G., and Gallarate, M. (2019). Development of Solid Lipid Nanoparticles by Cold Dilution of Microemulsions: Curcumin Loading, Preliminary In Vitro Studies, and Biodistribution. Nanomaterials, 9.","DOI":"10.3390\/nano9020230"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jcis.2014.04.057","article-title":"Physicochemical characterization of solid lipid nanoparticles (SLNs) prepared by a novel microemulsion technique","volume":"428","author":"Shah","year":"2014","journal-title":"J. Colloid Interface Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/10837450.2011.591804","article-title":"A novel lipid nanocarrier for insulin delivery: Production, characterization and toxicity testing","volume":"18","author":"Fangueiro","year":"2013","journal-title":"Pharm. Dev. Technol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Barbosa, T.C., Nascimento, L.E.D., Bani, C., Almeida, T., Nery, M., Santos, R.S., Menezes, L.R.O., Zielinska, A., Fernandes, A.R., and Cardoso, J.C. (2019). Development, Cytotoxicity and Eye Irritation Profile of a New Sunscreen Formulation Based on Benzophenone-3-poly(epsilon-caprolactone) Nanocapsules. Toxics, 7.","DOI":"10.3390\/toxics7040051"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.colsurfb.2011.03.035","article-title":"Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): High pressure homogenization versus ultrasound","volume":"86","author":"Silva","year":"2011","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.colsurfb.2010.07.029","article-title":"Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC","volume":"81","author":"Egea","year":"2010","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_67","unstructured":"Asiri, A.M., and Mohammad, A. (2018). 10\u2014Polymer nanoparticle carriers in drug delivery systems: Research trend. Applications of Nanocomposite Materials in Drug Delivery, Woodhead Publishing."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2217\/nnm.12.119","article-title":"Preparing amorphous hydrophobic drug nanoparticles by nanoporous membrane extrusion","volume":"8","author":"Guo","year":"2013","journal-title":"Nanomedicine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1208\/s12249-018-1217-7","article-title":"In vitro SPF and Photostability Assays of Emulsion Containing Nanoparticles with Vegetable Extracts Rich in Flavonoids","volume":"20","author":"Cefali","year":"2018","journal-title":"Aaps Pharmscitech"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1007\/s11095-010-0323-3","article-title":"Bottom-up preparation techniques for nanocrystals of lipophilic drugs","volume":"28","author":"Frijlink","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Cardea, S., and De Marco, I. (2020). Cellulose Acetate and Supercritical Carbon Dioxide: Membranes, Nanoparticles, Microparticles and Nanostructured Filaments. Polymers, 12.","DOI":"10.3390\/polym12010162"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Andrade, L.N., Oliveira, D.M.L., Chaud, M.V., Alves, T.F.R., Nery, M., da Silva, C.F., Gonsalves, J.K.C., Nunes, R.S., Correa, C.B., and Amaral, R.G. (2019). Praziquantel-Solid Lipid Nanoparticles Produced by Supercritical Carbon Dioxide Extraction: Physicochemical Characterization, Release Profile, and Cytotoxicity. Molecules, 24.","DOI":"10.3390\/molecules24213881"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Diniz, F.R., Maia, R.C.A.P., Rannier, L., Andrade, L.N., Chaud, M.V., da Silva, C.F., Corr\u00eaa, C.B., de Albuquerque Junior, R.L.C., da Costa, L.P., and Souto, E.B. (2020). Silver nanoparticles-composing alginate\/gelatin hydrogel improves wound healing in vivo. Nanomaterials, 10.","DOI":"10.3390\/nano10020390"},{"key":"ref_74","first-page":"11","article-title":"Manufacturing nanomaterials: From research to industry","volume":"1","author":"Charitidis","year":"2014","journal-title":"Manuf. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40199-016-0163-8","article-title":"Opportunities and obstacles to the development of nanopharmaceuticals for human use","volume":"24","author":"Abdollahi","year":"2016","journal-title":"Daru J. Pharm. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2147\/IJN.S65526","article-title":"Nanopharmaceuticals (part 2): Products in the pipeline","volume":"10","author":"Weissig","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/etc.3039","article-title":"Nanopharmaceuticals: Tiny challenges for the environmental risk assessment of pharmaceuticals","volume":"35","author":"Berkner","year":"2016","journal-title":"Environ. Toxicol. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.2147\/IJN.S46900","article-title":"Nanopharmaceuticals (part 1): Products on the market","volume":"9","author":"Weissig","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_79","first-page":"629681","article-title":"Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials","volume":"2013","author":"Wang","year":"2013","journal-title":"J. Nanomater."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/ptr.6171","article-title":"Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases","volume":"32","author":"Abenavoli","year":"2018","journal-title":"Phytother. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157340721001140724145924","article-title":"Nutraceuticals: Beyond the diet before the drugs","volume":"10","author":"Santini","year":"2014","journal-title":"Curr. Bioact. Compd."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Santini, A., and Novellino, E. (2017). To Nutraceuticals and Back: Rethinking a Concept. Foods, 6.","DOI":"10.3390\/foods6090074"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1111\/bph.13636","article-title":"Nutraceuticals in hypercholesterolaemia: An overview","volume":"174","author":"Santini","year":"2017","journal-title":"Br. J. Pharm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejps.2016.09.003","article-title":"Nutraceuticals: A paradigm of proactive medicine","volume":"96","author":"Santini","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/17512433.2018.1464911","article-title":"Nutraceuticals-shedding light on the grey area between pharmaceuticals and food","volume":"11","author":"Santini","year":"2018","journal-title":"Expert Rev. Clin. Pharm."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/13543776.2018.1552260","article-title":"A decade of nutraceutical patents: Where are we now in 2018?","volume":"28","author":"Daliu","year":"2018","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Saura-Calixto, F., and P\u00e9rez-Jim\u00e9nez, J. (2018). Extractable and Non-extractable polyphenols: An overview. Non-Extractable Polyphenols and Carotenoids: Importance in Human Nutrition and Health, Royal Society of Chemistry.","DOI":"10.1039\/9781788013208"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Durazzo, A., D\u2019Addezio, L., Camilli, E., Piccinelli, R., Turrini, A., Marletta, L., Marconi, S., Lucarini, M., Lisciani, S., and Gabrielli, P. (2018). From Plant Compounds to Botanicals and Back: A Current Snapshot. Molecules, 23.","DOI":"10.3390\/molecules23081844"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17512433.2019.1552135","article-title":"From pharmaceuticals to nutraceuticals: Bridging disease prevention and management","volume":"12","author":"Daliu","year":"2019","journal-title":"Expert Rev. Clin. Pharm."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Durazzo, A., and Lucarini, M. (2019). Extractable and Non-Extractable Antioxidants. Molecules, 24.","DOI":"10.3390\/molecules24101933"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1002\/ptr.6419","article-title":"Polyphenols: A concise overview on the chemistry, occurrence, and human health","volume":"33","author":"Durazzo","year":"2019","journal-title":"Phytother. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"9","DOI":"10.30744\/brjac.2179-3425.2018.5.20.9-11","article-title":"A current shot and re-thinking of antioxidant research strategy","volume":"5","author":"Durazzo","year":"2018","journal-title":"Braz. J. Anal. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bcp.13496","article-title":"Nutraceuticals: Opening the debate for a regulatory framework","volume":"84","author":"Santini","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_94","first-page":"6055","article-title":"Natural product-based nanomedicine: Recent advances and issues","volume":"10","author":"Watkins","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cis.2018.08.007","article-title":"Lipid nanocarriers for the loading of polyphenols\u2014A comprehensive review","volume":"260","author":"Teixeira","year":"2018","journal-title":"Adv. Colloid Interface Sci."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Singh, B. (2018). Nanonutraceuticals, CRC Press. [1st ed.].","DOI":"10.1201\/9781351138949"},{"key":"ref_97","first-page":"305","article-title":"Encapsulation of nutraceuticals in novel drug delivery systems","volume":"Volume 4","author":"Grumezescu","year":"2016","journal-title":"Nutraceuticals"},{"key":"ref_98","first-page":"127","article-title":"Rates and reasons for lack of persistence with anti-osteoporotic drugs: Analysis of the Campania region database","volume":"13","author":"Iolascon","year":"2016","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.2147\/PPA.S164819","article-title":"Adherence to chronic medication in older populations: Application of a common protocol among three European cohorts","volume":"12","author":"Menditto","year":"2018","journal-title":"Patient Prefer. Adherence"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"682503","DOI":"10.1155\/2015\/682503","article-title":"Self-Assessment of Adherence to Medication: A Case Study in Campania Region Community-Dwelling Population","volume":"2015","author":"Menditto","year":"2015","journal-title":"J. Aging Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12905-017-0424-9","article-title":"Differences in drug use between men and women: An Italian cross sectional study","volume":"17","author":"Putignano","year":"2017","journal-title":"BMC Women\u2019s Health"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12913-016-1411-9","article-title":"Italian translation and cultural adaptation of the communication assessment tool in an outpatient surgical clinic","volume":"16","author":"Scala","year":"2016","journal-title":"BMC Health Serv. Res."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Souto, E.B., Souto, S.B., Campos, J.R., Severino, P., Pashirova, T.N., Zakharova, L.Y., Silva, A.M., Durazzo, A., Lucarini, M., and Izzo, A.A. (2019). Nanoparticle Delivery Systems in the Treatment of Diabetes Complications. Molecules, 24.","DOI":"10.3390\/molecules24234209"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Vieira, R., Souto, S.B., Sanchez-Lopez, E., Machado, A.L., Severino, P., Jose, S., Santini, A., Fortuna, A., Garcia, M.L., and Silva, A.M. (2019). Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I. Pharmaceuticals, 12.","DOI":"10.3390\/ph12040152"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Vieira, R., Souto, S.B., S\u00e1nchez-L\u00f3pez, E., Machado, A.L., Severino, P., Jose, S., Santini, A., Silva, A.M., Fortuna, A., and Garc\u00eda, M.L. (2019). Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II. J. Clin. Med., 8.","DOI":"10.3390\/jcm8091332"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4103\/2230-973X.107008","article-title":"Delivery of nutraceuticals using nanotechnology","volume":"2","author":"Wiwanitkit","year":"2012","journal-title":"Int. J. Pharm. Investig."},{"key":"ref_107","first-page":"75","article-title":"Nanoparticulate carriers for oral pharmaceutics and nutraceutics","volume":"65","author":"Lopes","year":"2010","journal-title":"Pharmazie."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.2174\/0929867325666181031105603","article-title":"Linseed Essential Oil\u2013Source of Lipids as Active Ingredients for Pharmaceuticals and Nutraceuticals","volume":"26","author":"Campos","year":"2019","journal-title":"Curr. Med. Chem."}],"container-title":["Nanomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-4991\/10\/3\/455\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:03:53Z","timestamp":1760173433000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-4991\/10\/3\/455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":108,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["nano10030455"],"URL":"https:\/\/doi.org\/10.3390\/nano10030455","relation":{},"ISSN":["2079-4991"],"issn-type":[{"value":"2079-4991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]}}}